Lpath, Inc. Sets Investor Update Conference Call for Thursday, January 3, 2013 at 4:30 p.m. ET
Published: Dec 27, 2012
SAN DIEGO, CA--(Marketwire - December 26, 2012) - Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, will hold a conference call on Thursday, January 3, 2013 at 4:30 p.m. Eastern time to provide an update on its Nexus Phase 2 trial for iSONEP™, an ocular drug candidate, as well as outline the company's 2013 objectives.
Lpath President and CEO Scott Pancoast will host the presentation, followed by a question-and-answer period.
Date: Thursday, January 3, 2013
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-in number: 1-877-941-1427
International dial-in: 1-480-629-9664
Conference ID number: 4584568
Webcast and replay: http://public.viavid.com/index.php?id=102952
Please call the conference telephone number 5-10 minutes prior to the start time. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A telephone replay of the call will be available after 7:30 p.m. Eastern time on the same day and until February 3, 2013.
Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay pin number: 4584568
San Diego-based Lpath, Inc., a therapeutic antibody company, is the category leader in lipid-targeted therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates: iSONEP™ is currently in a Phase 2 trial for wet AMD; ASONEP™ is scheduled to begin a Phase 2a trial in Renal Cell Carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in neuropathic pain, neurotrauma, and other diseases. For more information, visit www.Lpath.com.
Scott R. Pancoast
President & CEO
Lpath Investor Relations
Liolios Group, Inc.
Ron Both: Email Contact
Geoffrey Plank: Email Contact